{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:11:16Z","timestamp":1778253076769,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical outcomes in patients with glioblastoma and low Karnofsky Performance Scale (KPS) in the inpatient setting are rarely described. Limited survival data and high symptom burden complicate decision-making. This study describes patient-centered outcomes in functionally debilitated patients with newly diagnosed glioblastoma following cancer-directed treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed charts of patients with newly diagnosed glioblastoma who received radiotherapy (RT) while hospitalized. Patient, tumor, and treatment characteristics were included in univariable Cox regression and logistic models to assess associations with overall survival (OS) and discharge home. Multivariable models included factors significant on univariable analysis. OS was estimated by the Kaplan-Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 52 patients (median age: 68 years, range: 21-85), median KPS was 50 (range: 30-60). All underwent RT and 50 (96%) received concurrent temozolomide; 12 (23%) received bevacizumab, and 46 (88%) completed planned RT. Median length of stay (LOS) was 29 days (range: 20-65). Only 40% of patients were able to participate in decision-making. Specialty palliative care consultation was provided to 16 (31%). Median OS was 5.82 months. In multivariable analysis, lower KPS remained the sole factor significantly associated with increased risk of death (P\u2009=\u2009.002) and decreased odd of discharge home (P\u2009=\u2009.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inpatient treatment for functionally disabled patients with glioblastoma was associated with prolonged LOS and poor outcomes. These findings highlight opportunities for early incorporation of specialty palliative care to multimodal cancer-directed therapies to optimize symptom management, elicit patient values and preferences, and facilitate goal-concordant decision-making. Prospective studies are necessary to identify predictors of functional recovery and treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/nop\/npaf109","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:56:12Z","timestamp":1761134172000},"page":"312-321","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6424-1630","authenticated-orcid":false,"given":"Neil","family":"Sielski","sequence":"first","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne S","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-8911","authenticated-orcid":false,"given":"William E","family":"Rosa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5915","authenticated-orcid":false,"given":"Brandon S","family":"Imber","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-7442","authenticated-orcid":false,"given":"Luke R G","family":"Pike","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis P","family":"Voigt","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pain & Critical Care Medicine, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren R","family":"Schaff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor T","family":"Gavrilovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan C","family":"Carver","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Rosenblum","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-1670","authenticated-orcid":false,"given":"Viviane","family":"Tabar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-8518","authenticated-orcid":false,"given":"Thomas","family":"Kaley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-0251","authenticated-orcid":false,"given":"Elena","family":"Pentsova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026050810214319000_npaf109-B1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other Central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026050810214319000_npaf109-B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026050810214319000_npaf109-B3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026050810214319000_npaf109-B4","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"key":"2026050810214319000_npaf109-B5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026050810214319000_npaf109-B6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026050810214319000_npaf109-B7","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International atomic energy agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026050810214319000_npaf109-B8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050810214319000_npaf109-B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.radonc.2018.01.017","article-title":"Improved cost-effectiveness of short-course radiotherapy in elderly and\/or frail patients with glioblastoma","volume":"127","author":"Ghosh","year":"2018","journal-title":"Radiother Oncol"},{"key":"2026050810214319000_npaf109-B10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/neuonc\/noaa019","article-title":"A phase I\/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes","volume":"22","author":"Azoulay","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026050810214319000_npaf109-B11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00432-021-03770-9","article-title":"Radiotherapy for glioblastoma patients with poor performance status","volume":"148","author":"Schr\u00f6der","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026050810214319000_npaf109-B12","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.31557\/apjcp.2022.23.7.2317","article-title":"A randomized study of short course (one week) radiation therapy with or without temozolomide in elderly and\/or frail patients with newly diagnosed glioblastoma (GBM)","volume":"23","author":"Thakur","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026050810214319000_npaf109-B13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","article-title":"No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients","volume":"26","author":"Hegi","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026050810214319000_npaf109-B14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/neuonc\/noab279","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"24","author":"Mohile","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026050810214319000_npaf109-B15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026050810214319000_npaf109-B16","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1001\/jama.2016.16840","article-title":"Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis","volume":"316","author":"Kavalieratos","year":"2016","journal-title":"JAMA"},{"key":"2026050810214319000_npaf109-B17","doi-asserted-by":"publisher","first-page":"j2925","DOI":"10.1136\/bmj.j2925","article-title":"Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis","volume":"357","author":"Gaertner","year":"2017","journal-title":"BMJ"},{"key":"2026050810214319000_npaf109-B18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/nop\/npw022","article-title":"Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care","volume":"4","author":"Hemminger","year":"2017","journal-title":"Neurooncol Pract"},{"key":"2026050810214319000_npaf109-B19","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.3390\/cancers13122867","article-title":"Palliative care service utilization and advance care planning for adult glioblastoma patients: a systematic review","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026050810214319000_npaf109-B20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/neuonc\/nov156","article-title":"Rates and risks for late referral to hospice in patients with primary malignant brain tumors","volume":"18","author":"Diamond","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026050810214319000_npaf109-B21","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.24.00542","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050810214319000_npaf109-B22","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00520-021-06514-0","article-title":"Caregiver burden by treatment and clinical characteristics of patients with glioblastoma","volume":"30","author":"Au","year":"2022","journal-title":"Support Care Cancer"},{"key":"2026050810214319000_npaf109-B23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-018-2800-1","article-title":"Clinical routine assessment of palliative care symptoms and concerns and caregiver burden in glioblastoma patients: an explorative field study","volume":"138","author":"Seibl-Leven","year":"2018","journal-title":"J Neurooncol"},{"key":"2026050810214319000_npaf109-B24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/nop\/npv060","article-title":"Existential distress among caregivers of patients with brain tumors: a review of the literature","volume":"3","author":"Applebaum","year":"2016","journal-title":"Neurooncol Pract"},{"key":"2026050810214319000_npaf109-B25","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.wneu.2024.08.114","article-title":"Caregivers\u2019 perspective and burden of the end-of-life phase of patients with glioblastoma: a multicenter retrospective study","volume":"192","author":"Gulino","year":"2024","journal-title":"World Neurosurg."},{"key":"2026050810214319000_npaf109-B26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cam4.653","article-title":"Associations between advanced cancer patients\u2019 survival and family caregiver presence and burden","volume":"5","author":"Dionne-Odom","year":"2016","journal-title":"Cancer Med"},{"key":"2026050810214319000_npaf109-B27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/spcare-2023-004524","article-title":"Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study","volume":"14","author":"Giusti","year":"2024","journal-title":"BMJ Support Palliat Care"},{"key":"2026050810214319000_npaf109-B28","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"Lancet"},{"key":"2026050810214319000_npaf109-B29","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026050810214319000_npaf109-B30","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cancers14133161","article-title":"Survival outcomes and prognostic factors in glioblastoma","volume":"14","author":"Brown","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026050810214319000_npaf109-B31","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1200\/JOP.18.00346","article-title":"1-2-3 Project: a quality improvement initiative to normalize and systematize palliative care for all patients with cancer in the outpatient clinic setting","volume":"14","author":"Desai","year":"2018","journal-title":"J Oncol Pract"},{"key":"2026050810214319000_npaf109-B32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1474-4422(23)00129-1","article-title":"Palliative care to support the needs of adults with neurological disease","volume":"22","author":"Kluger","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026050810214319000_npaf109-B33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jpainsymman.2025.02.008","article-title":"Post-acute transition to home with supportive care (PATHS): a novel nurse practitioner-led telehealth intervention to improve end-of-life oncology care","volume":"69","author":"Rosa","year":"2025","journal-title":"J Pain Symptom Manage"},{"key":"2026050810214319000_npaf109-B34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jpainsymman.2024.08.024","article-title":"Continuum: a postdischarge supportive care intervention for hospitalized patients with advanced cancer","volume":"68","author":"Lage","year":"2024","journal-title":"J Pain Symptom Manage"},{"key":"2026050810214319000_npaf109-B35","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/s12912-025-03189-4","article-title":"Effectiveness of transitional care interventions in patients with serious illness and their caregivers: a systematic review and metanalysis of randomized controlled trial","volume":"24","author":"Di Nitto","year":"2025","journal-title":"BMC Nurs"},{"key":"2026050810214319000_npaf109-B36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3171\/2014.9.jns14193","article-title":"Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma","volume":"122","author":"Sun","year":"2015","journal-title":"J Neurosurg"},{"key":"2026050810214319000_npaf109-B37","doi-asserted-by":"publisher","first-page":"CNS64","DOI":"10.2217\/cns-2020-0018","article-title":"Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation: a retrospective cohort study","volume":"9","author":"Warren","year":"2020","journal-title":"CNS Oncol"},{"key":"2026050810214319000_npaf109-B38","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/jrr\/rrx103","article-title":"Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival","volume":"59","author":"Pollom","year":"2018","journal-title":"J Radiat Res"},{"key":"2026050810214319000_npaf109-B39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-021-08834-0","article-title":"A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)","volume":"21","author":"Arakawa","year":"2021","journal-title":"BMC Cancer"},{"key":"2026050810214319000_npaf109-B40","doi-asserted-by":"publisher","first-page":"101813","DOI":"10.1016\/j.adro.2025.101813","article-title":"Comparative outcomes of standard radiotherapy and 5-fraction adaptive stereotactic radiation therapy in newly diagnosed glioblastoma: a propensity score-matched analysis","volume":"10","author":"Dohopolski","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"2026050810214319000_npaf109-B41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","article-title":"Radiation therapy for glioblastoma: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology guideline","volume":"35","author":"Sulman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026050810214319000_npaf109-B42","doi-asserted-by":"publisher","first-page":"110696","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf109\/64925115\/npaf109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/2\/312\/64925115\/npaf109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/2\/312\/64925115\/npaf109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:21:47Z","timestamp":1778250107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/2\/312\/8300992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf109","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,24]]}}}